Agreement between CRO and Principal Investigator Sample Clauses

Agreement between CRO and Principal Investigator. Study conduct by Principal Investigator and Principal Investigator’s associated obligations to CRO and Pfizer are documented in a separate agreement between CRO and Principal Investigator. The agreement between CRO and Principal Investigator also stipulates remuneration for the Principal Investigator and all members of the study team for conducting the Study. Institution confirms that it is aware of this separate agreement. Institution further confirms that it has received a copy of that agreement (either with or without inclusion of the Study Budget attachment) or has been otherwise satisfactorily informed as to Principal Investigator’s Study- related rights and responsibilities.
Sample 1See All (5)
AutoNDA by SimpleDocs
Agreement between CRO and Principal Investigator. Study conduct by Principal Investigator and Principal Investigator’s associated obligations to CRO and Pfizer are documented in a separate agreement between CRO and Principal Investigator. The Health Services Provider confirms that it is aware of this separate agreement. The Health Services Provider further confirms that it has received a copy of that agreement (either with or without inclusion of the Study Budget attachment) or has been otherwise satisfactorily informed as to Principal Investigator’s Study-related rights and responsibilities. S mlouva mezi CRO a Hlavním zkoušejícím. Bližší podmínky provádění Studie Hlavním zkoušejícím a související závazky Hlavního zkoušejícího vůči CRO a společnosti Pfizer jsou uvedeny v samostatné smlouvě mezi CRO a Hlavním zkoušejícím. Poskytovatel zdravotních služeb potvrzuje, že si je vědom této samostatné smlouvy. Poskytovatel zdravotních služeb dále potvrzuje, že obdržel dále uvedené smlouvy (ať již s přílohou Rozpočtu studie, anebo bez ní) nebo byl jiným dostatečným způsobem informován o právech a povinnostech Hlavního zkoušejícího souvisejících se Studií.
Sample 1
Agreement between CRO and Principal Investigator. Study conduct by Principal Investigator and Principal Investigator’s associated obligations to CRO and Pfizer are documented in a separate agreement between CRO and Principal Investigator. Institution confirms that it is aware of this separate 1.3 Smlouva mezi CRO a hlavním zkoušejícím. Úprava vedení klinického hodnocení hlavním zkoušejícím a související závazky hlavního zkoušejícího vůči CRO a společnosti Pfizer jsou uvedeny v samostatné smlouvě mezi CRO a hlavním zkoušejícím. Zdravotnické zařízení potvrzuje, že si je agreement. Institution is not liable for the taxation of Principal Investigator´s study team members. vědoma této samostatné smlouvy. Zdravotnické zařízení neodpovídá za zdanění příjmů členů týmu hlavního zkoušejícího.
Sample 1

Related to Agreement between CRO and Principal Investigator

  • Compliance Between Individual Contract and Master Agreement Any individual contract between the Board and an individual employee, heretofore or hereafter executed, shall be subject to and consistent with the terms and conditions of this Agreement. If an individual contract contains any language inconsistent with this Agreement, this Agreement, during its duration, shall be controlling.

  • Cooperation Between the Parties The College and UFE shall supply each other with requested information reasonably needed to facilitate the processing of the grievance. Meetings to discuss any grievance shall be scheduled at mutually convenient times.

  • Settlement of Disputes between the Contracting Parties 1. Disputes between the Contracting Parties concerning the interpretation or application of this Agreement should, if possible, be settled through diplomatic channels.

  • Settlement of Disputes between Contracting Parties (1) Disputes between Contracting Parties regarding the interpretation or application of the provisions of this Agreement shall be settled through diplomatic channels.

  • Disputes between the Contracting Parties 1. Any dispute between the Contracting Parties concerning the interpretation or application of this Agreement shall, as far as possible, be settled through negotiation.

  • Negotiation Between Executives The parties shall first attempt to resolve any dispute arising out of this Order by prompt negotiation between executives who have authority to settle the matter.

  • What Will Happen After We Receive Your Letter When we receive your letter, we must do two things:

  • Pharmacovigilance Agreement Within [***] after the Effective Date, BMS and the Company (under the guidance of their respective Pharmacovigilance Departments, or equivalent thereof) shall define and finalize the responsibilities the Parties shall employ to protect patients and promote their well-being in connection with the use of the Licensed Compound(s) until such time that all pharmacovigilance responsibilities have transferred from BMS to Company. These responsibilities shall include mutually acceptable guidelines and procedures for the receipt, investigation, recordation, communication, and exchange (as between the Parties) of adverse event reports, pregnancy reports, and any other information concerning the safety of any Licensed Compound(s). Such guidelines and procedures shall be in accordance with, and enable the Parties and their Affiliates to fulfill, local and international regulatory reporting obligations to government authorities. Furthermore, such agreed procedures shall be consistent with relevant International Council for Harmonization (ICH) guidelines, except where said guidelines may conflict with existing local regulatory safety reporting requirements, in which case local reporting requirements shall prevail. Until such guidelines and procedures are set forth in a written agreement between the Parties (hereafter referred to as the “Pharmacovigilance Agreement”), the Party responsible for pharmacovigilance prior to execution of this Agreement shall have sole Pharmacovigilance responsibility for the Licensed Compound(s) subject to all applicable regulations and guidelines. In the event that this Agreement is terminated, the Parties agree to implement the necessary procedures and practices to ensure that any outstanding pharmacovigilance reporting obligations are fulfilled. Certain information marked as [***] has been excluded from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.

  • Collaboration Agreement The Collaboration Agreement shall not have been terminated in accordance with its terms and shall be in full force and effect.

  • Agreement Scope The scope of this Agreement is as prescribed in section 46 of the Act, setting out: • the health services to be provided to the State by the HSP, • the TTR in support of the health services to be provided, • the funding to be provided to the HSP for the provision of the health services, including the way in which the funding is to be provided, • the performance measures and operational targets for the provision of the health services by the HSP, • how the evaluation and review of results in relation to the performance measures and operational targets is to be carried out, • the performance data and other data to be provided by the HSP to the Department CEO, including how, and how often, the data is to be provided, and • any other matter the Department CEO considers relevant to the provision of the health services by the HSP. Where appropriate, reference will be made in this Agreement to Policy Frameworks issued by the Department CEO pursuant to Part 3, Division 2 of the Act.

Time is Money Join Law Insider Premium to draft better contracts faster.